ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31

Adagene Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026

$2.29+0.23 (+11.17%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Dividends

Adagene has not reported a dividend

No dividend per share appears in Adagene's annual filings since fiscal 2017.

Where these numbers come from

Parsed from the XBRL in Adagene's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADAG.

Revenue growth7332.8% · median -25.3%

Operating margin-279.5% · median -565.4%

Net margin-229.6% · median -523.3%

Company	Revenue	Growth
CTMX	$18.30M	-87.0%
ADAG	$7.67M	+7332.8%
HCWB	$6.66M	+700.2%
BOLT	$4.70M	+12.8%
IMNM	$4.02M	-63.3%
CBIO	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 128
Held by institutions: 32.5%
Auditor: PricewaterhouseCoopers Zhong TianLLP
SEC CIK: 1818838

Advertisement
300 × 250